2023-504830-23-00招募中3 期
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- Genmab A/S
- 入组人数
- 253
- 试验地点
- 90
- 主要终点
- Overall survival (OS)
研究概览
简要总结
Compare the clinical efficacy of epcoritamab to standard of care (SOC)(R-GemOx or BR)
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- •Must be at least 18 years of age
- •Subject must sign an ICF indicating that the purpose of the trial and the procedures required for the trial are understood, and indicating that the subject is willing to participate in the trial prior to initiating any other trial-related assessments or procedures
- •ECOG PS score of 0-2
- •One of the confirmed histologies below wiht CD20 positivity: a. DLBCL, NOS (according to the WHO 2016 classification), and including de novo or histologically transformed from follicular lymphoma (FL). b. "Double-hit" or "triple-hit" DLBCL (technically classified in WHO 2016 as HGBCL, with MYC and BCL2 and / or BCL6 translocations), including de novo or histologically transformed from FL c. FL Grade 3B d. T-cell/histiocyte-rich large B-cell lymphoma
- •CD20-positivity at representative tumor biopsy based on the pathology report;
- •Relapsed or refractory disease and previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAbcontaining combination chemotherapy since lymphoma diagnosis (ie,having received R-CHOP or an equivalent regimen that would be considered adequate first-line treatment for DLBCL);
- •Failed previous HDT-ASCT or not eligible for HDT-ASCT at screening. If ineligible for HDT-ASCT, the decision must have been based on age, performance status, comorbidity, and/or insufficient response to prior treatment;
- •Has measurable disease: a. A fluorodeoxyglucose-positron emission tomography (FDG- PET) scan demonstrating positive lesion(s) compatible with computed tomography (CT) or magnetic resoncance imagining (MRI)-defined anatomical tumor sites b. ≥1 measurable nodal lesion (long axis >1.5 cm and short axis >1.0 cm) and/or ≥1 measurable extra-nodal lesion (long axis >1.0 cm) on CT scan or MRI;
- •Absolute neutrophil count ≥1.0 x 10e9/L (growth factor permitted)
- •Platelet count >75 x 10e9/L (or >50 x 10e9/L if bone marrow involvement or splenomegaly)
- •A female subject must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the entire trial, until 12 months after the last administration of trial treatment
- •Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) level ≤3 times the upper limit of normal (x ULN), unless enzyme elevation is due to a nonhepatic origin or lymphoma involvement of the liver and ALT and AST levels are ≤5 xULN
- •Total bilirubin level ≤2 x ULN, unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin or lymphoma involvement of the liver and total bilirubin is ≤5xULN
- •Estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 as calculated by Cockcroft-Gault
- •PT/INR/aPTT ≤1.5 xULN, unless receiving anticoagulation
- •A female subject with reproductive potential must agree to use adequate contraception during the trial, and for 12 months after the last administration of trial treatment. Adequate contraception is defined as highly effective methods of contraception
- •A female subject of childbearing potential must have a negative serum (beta-hCG) pregnancy test at screening and a negative serum or urine pregnancy test before treatment administration on Day 1 of every cycle
- •A male subject who is sexually active with a female of reproductive potential and has not had a vasectomy must agree to use a barrier method of birth control and (ie, condom) must agree not to donate sperm during the trial and for 12 months after receiving the last administration of trial treatment.
- •Life expectancy >2 months on SOC treatment.
排除标准
- •Primary central nervous system (CNS) tumor or known CNS involvement as assessed by brain MRI at screening or by CT and lumbar puncture (if MRI contraindicated)
- •Has known past or current malignancy other than inclusion diagnosis, except for: a. Cervical carcinoma of Stage 1B or less b. Non-invasive basal cell or squamous cell skin carcinoma c. Non-invasive, superficial bladder cancer d. Prostate cancer with a current PSA level <0.1 ng/mL e. Any curable cancer with a complete response of >2 years duration
- •Contraindication to all uric acid lowering agents
- •Any prior therapy with a bispecific antibody targeting CD3 and CD20
- •A woman of childbearing potential with a positive serum or urine pregnancy test at screening. Female subjects must also agree not to breastfeed during the entire trial and until 12 months after the last administration of study drug
- •Clinically significant liver disease, including active hepatitis, current alcohol abuse, or cirrhosis
- •Active tuberculosis or history of completed treatment for active tuberculosis within the past 12 months
- •Receiving immunostimulatory agent
- •Prior allogeneic hematopoietic stem cell transplantation
- •History of severe allergic or anaphylactic reactions to anti-CD20 antibody therapy
- •Contraindication to any component of SOC regimen selected prior to randomization
- •Seizure disorder requiring anti-epileptic therapy
- •Major surgery within 4 weeks prior to randomization
- •Chemotherapy and other non-investigational antineoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to randomization
- •ASCT within 100 days of randomization
- •Treatment with CAR-T therapy within 100 days prior to randomization
- •Receiving immunosuppressive therapy, including more than the equivalent of ≥20 mg of prednisolone daily, unless for control of lymphoma or intermittent prophylaxis/treatment of allergic reactions
- •Any investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to randomization
- •Has known or suspected allergies, hypersensitivity, or intolerance to epcoritamab or its excipients
- •Vaccination with live vaccines within 28 days prior to randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever,rabies, Bacillus Calmette–Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed. Experimental and/or non authorized severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccinations are not allowed
- •Clinically significant cardiovascular disease
- •Screening 12-lead ECG showing a baseline QT interval as corrected by Fridericia's formula (QTcF) >470 msec
- •Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results
- •Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic treatment at time of randomization
- •Known history of seropositivity for human immunodeficiency virus (HIV) infection. Note: HIV testing is required at screening only if required per local health authorities or institutional standards
- •Active hepatitis B virus (HBV) (DNA polymerase chain reaction [PCR]-positive) or hepatitis C (RNA PCR-positive infection). Subjects with evidence of prior HBV but who are PCR-negative are permitted in the trial but should receive prophylactic antiviral therapy. Subjects who received treatment for hepatitis C that was intended to eradicate the virus may participate if hepatitis C RNA levels are undetectable
结局指标
主要结局
Overall survival (OS)
Overall survival (OS)
Progression-free survival (PFS) determined by Lugano criteria per independent review committee (IRC) assessment
Progression-free survival (PFS) determined by Lugano criteria per independent review committee (IRC) assessment
次要结局
- Progression-free survival (PFS) determined by Lugano criteria per investigator assessment
- Overall response rate (ORR) determined by Lugano criteria per IRC assessment and investigator assessment
- Complete response (CR) rate determined by Lugano criteria per IRC assessment and investigator assessment
- Duration of response (DOR) determined by Lugano criteria per IRC assessment and investigator assessment
- Time to response (TTR) determined by Lugano criteria per IRC assessment and investigator
- Rate and duration of minimal residual disease (MRD) negative status
- PFS determined by Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC) per IRC assessment
- ORR determined by LYRIC per IRC assessment
- CR rate determined by LYRIC per IRC assessment
- DOR determined by LYRIC per IRC assessment
- TTR determined by LYRIC per IRC assessment
- Time to next anti-lymphoma therapy (TTNT)
- Incidence and severity of adverse events (AEs)
- Incidence and severity of changes in laboratory values
- Incidence of dose interruptions and delays
- Anti-epcoritamab antibody response
- Changes in lymphoma symptoms as measured by the Functional Assessment of Cancer Therapy – Lymphoma (FACT-Lym)
研究者
Trial Information
Scientific
Genmab A/S
研究点 (90)
Loading locations...
相似试验
招募中
2 期
EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.2023-504832-16-00Genmab A/S102
招募中
3 期
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Capsules Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma2024-510965-41-00AbbVie Deutschland GmbH & Co. KG94
招募中
3 期
A Phase 3 randomized clinical Study of Pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen as first line treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma2024-512015-47-00Incyte Corp.42
招募中
2 期
A trial to learn how well osimertinib with savolitinib works in people with non-small cell lung cancer (NSCLC) that has gotten worse after initial treatment with osimertinib.2024-512564-58-00AstraZeneca AB135
招募中
2 期
A study to assess the long-term safety and efficacy of a subcutaneous
formulation of efgartigimod in adults with chronic inflammatory
demyelinating polyneuropathy (an autoimmune disorder that affects the
peripheral nerves)Chronic Inflammatory Demyelinating Polyneuropathy2023-507885-21-00Argenx88